Anebulo Pharmaceuticals, Inc. ANEB
0.28 USD 0.00 (+0.00%)
Regular-session close
0.38 +0.10 +36.39%
After hours · Nov 18, 4:00 PM ET
0.8699 Day range 0.8699
0.001 52-week range 2.49
- YTD
- -72.28%
- 1 year
- -87.98%
News
defenseworld.net Anebulo Pharmaceuticals (ANEB) to Announce Earnings on Wednesday Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) is anticipated to post its Q4 2026 resultson Wednesday, September 23rd. Analysts expect the company to announce earnings of ($0.10) per share…
defenseworld.net Anebulo Pharmaceuticals (NASDAQ:ANEB) & Replimune Group (NASDAQ:REPL) Critical Comparison Replimune Group (NASDAQ: REPL - Get Free Report) and Anebulo Pharmaceuticals (NASDAQ: ANEB - Get Free Report) are both small-cap medical companies, but which is the better business? We will compare…
businesswire.com Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2026 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic…
businesswire.com Anebulo Pharmaceuticals Announces Intention to Voluntarily Delist from Nasdaq and Deregister with SEC AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic…
defenseworld.net Anebulo Pharmaceuticals (NASDAQ:ANEB) Trading Down 13.6% – What’s Next? Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s stock price dropped 13.6% on Thursday. The stock traded as low as $0.8031 and last traded at $0.8212. Approximately 42,620 shares were…
defenseworld.net Anebulo Pharmaceuticals (NASDAQ:ANEB) Stock Price Down 13.6% – What’s Next? Anebulo Pharmaceuticals, Inc. (NASDAQ: ANEB - Get Free Report)'s share price was down 13.6% during trading on Thursday. The company traded as low as $0.8031 and last traded at $0.8212. Approximately…
businesswire.com Anebulo Pharmaceuticals Announces Final Results of Tender Offer AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic…
businesswire.com Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Preliminary Results of Tender Offer.
businesswire.com Anebulo Pharmaceuticals Announces Its Intent to Commence a Self Tender Offer AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic…
businesswire.com Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports First Quarter Fiscal Year 2026 Financial Results and Recent Updates.
businesswire.com Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Recent Updates.
businesswire.com Anebulo Pharmaceuticals Announces First Patients Dosed in Phase 1 Single Ascending Dose Study of Intravenous Selonabant, under Development for Acute Cannabis-Induced Toxicity AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid-induced…
businesswire.com Anebulo Pharmaceuticals Approves Plan to Terminate Registration of Its Common Stock AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic…
businesswire.com Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2025 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic…
businesswire.com Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2025 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage pharmaceutical company developing novel solutions for people suffering from acute cannabis-induced toxic…
businesswire.com Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Announces Positive Regulatory Update for Selonabant in Acute Cannabis-Induced Toxicity in Children and Capital Raise.
businesswire.com Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Fourth Quarter and Fiscal Year 2024 Financial Results and Recent Updates.
businesswire.com Galehead Development to Collaborate With Rivian Automotive on Renewable Energy Project Development BOSTON--(BUSINESS WIRE)--Galehead Development, LLC (“Galehead”) and Rivian Automotive, LLC (“Rivian”) have entered into an agreement to collaborate on the development of renewable energy resources…
businesswire.com Anebulo Pharmaceuticals Reports Third Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals, Inc. (Nasdaq: ANEB), a clinical-stage biopharmaceutical company developing novel solutions for people suffering from acute cannabinoid…
businesswire.com Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates AUSTIN, Texas--(BUSINESS WIRE)--Anebulo Pharmaceuticals Reports Second Quarter Fiscal Year 2024 Financial Results and Recent Updates.
